CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,778,383 | +775.8% | 454,620 | +543.2% | 0.05% | +642.9% |
| Q2 2023 | $773,967 | +1.4% | 70,682 | -41.9% | 0.01% | +16.7% |
| Q4 2022 | $762,952 | +1073.8% | 121,683 | +711.1% | 0.01% | +500.0% |
| Q2 2021 | $65,000 | -98.2% | 15,003 | -97.0% | 0.00% | -98.6% |
| Q3 2020 | $3,630,000 | +545.9% | 501,368 | +211.9% | 0.07% | +762.5% |
| Q2 2020 | $562,000 | +577.1% | 160,764 | +185.8% | 0.01% | +60.0% |
| Q1 2020 | $83,000 | -79.1% | 56,250 | -27.7% | 0.01% | -58.3% |
| Q3 2019 | $398,000 | -90.3% | 77,800 | -86.4% | 0.01% | -91.7% |
| Q2 2019 | $4,097,000 | +1.7% | 572,200 | +88.6% | 0.14% | +3.6% |
| Q1 2019 | $4,029,000 | +2202.3% | 303,400 | +1266.7% | 0.14% | +1900.0% |
| Q4 2018 | $175,000 | +12.2% | 22,200 | +58.6% | 0.01% | 0.0% |
| Q3 2018 | $156,000 | -55.3% | 14,000 | -46.2% | 0.01% | -63.2% |
| Q2 2018 | $349,000 | +25.5% | 26,000 | -24.4% | 0.02% | -24.0% |
| Q3 2017 | $278,000 | – | 34,410 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |